GPC1 and non-small cell lung carcinoma: In contrast, the i.p. administration of anti-GPC1 mAb at 10 and 50 mg/kg once a week for 3 doses and then once every 10 days for 2 more doses appeared to attenuate the FGF signal transduction pathway in the orthotopic A549 NSCLC xenografts (Figure 10, Figure 11 and Figure 12).